The nation of Zimbabwe has declined a substantial US health deal valued at $367m (£272m) spanning five years because of the United States' insistence on confidential information.
The decision came to light after a government memo from December was disclosed, which showed President Emmerson Mnangagwa felt the agreement was "skewed".
An official representative later explained that the US was seeking genetic material for scientific study and profit but was unwilling to guarantee the resulting advantages from future treatments.
"We will now turn to the difficult and regrettable process of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for continued negotiations to secure a deal acceptable to both sides so the nation's critical HIV treatment initiative can be sustained.
Broader Context
This development comes after a similar case in Kenya, where a court suspended a similar health funding agreement after legal challenges were filed about the security of citizens' health data.
Since resuming office recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to enhance openness and responsibility.
As per reports, Sixteen nations in Africa have to date signed these new agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Agreement
The money for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to surrender its biological resources and data for a long time, with no corresponding assurance of benefiting from any medical innovations – like new medicines or tests – that could result from that provided information," his statement read.
"In essence, our nation would provide the basic resources for scientific discovery with no assurance that the resulting innovations would be available to our population if a future pandemic emerge."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining systems already established through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to deal with potential global health emergencies.
"This framework is intended to guarantee that when a country provides its samples, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the capability to develop them."
The government's concerns regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to continued dialogue with our US partners on how subsequent co-operation might be structured in a manner that honours the independence and dignity of both nations."
Health Experts Reaction
A leading public health body expressed it understood the government's concerns, but suggested that negotiations need to persist since much of the nation's Aids initiatives depended on external financing.
"Where technical issues arise, including those involving information security or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," the group added.
The situation highlights the continuing debate between receiving much-needed foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.